Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | KIT | P10721 | 3/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | LYN | P07948 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | FLT4 | P35916 | 2/20 | 0.35 |
| ▸ | BLK | P51451 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.35 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010929 | 0.80 | BTK (0.35) | BTK | |
| SCHEMBL16475286 | 0.75 | PDPK1 (0.56) | BTKPDPK1GAAAURKATGFBR1 | |
| SCHEMBL9605473 | 0.73 | CHEK1 (0.34) | BTKPDPK1GAAAURKATGFBR1 | |
| SCHEMBL17028038 | 0.72 | GAA (0.56) | BTKPDPK1GAAAURKAAURKB | |
| SCHEMBL5550935 | 0.72 | BTK (0.43) | BTKPDPK1GAAAURKAAURKB | |
| SCHEMBL25950681 | 0.71 | BTK (0.43) | BTKPDPK1GAAKDRKIT | |
| SCHEMBL27010932 | 0.68 | FFAR1 (0.32) | — | |
| SCHEMBL6115796 | 0.67 | BTK (1.00) | BTKAURKAAURKBKDRKIT | |
| SCHEMBL20153657 | 0.67 | P2RX3 (0.33) | — | |
| SCHEMBL1703256 | 0.66 | BTK (0.67) | BTKPDPK1AURKAAURKBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | BTK 3707/4885PDPK1 1292/4885GAA 790/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | BTK 2336/4885PDPK1 128/4885GAA 2096/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | BTK 2336/4885PDPK1 128/4885GAA 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.